Antibiotics become ineffective when bacteria either develop a resistance to them or patients fail to finish a course. Thankfully, a new drug recently approved by the Food and Drug Administration (FDA) can solve both these problems. Orbactiv will be used to treat acute bacterial skin and skin structure infections (ABSSSI). The innovative medication can provide help to patients who have a resistance to older antibiotics and delivers a complete course of treatment in only one dose.

Orbactiv is the creation of Medicines Co., and is classified as a generic vancomycin, the go-to treatment option for the drug-resistant MSRA, Medical Daily reported.

What makes Obactiv so extraordinary is its ability to comprise a complete full course of therapy in one 1200-milligram dose. This is something no other drugs in the market are capable of doing. Other antibiotics like vancomycin require intravenous infusions over the course of seven to 10 days.

Orbactiv did well in its clinical trials. Researchers administered the drug to 1,959 patient and results were found to be more effective than treatment with vancomycin. Side effects ranged from diarrhea, vomiting, headache, and nausea. However, it was noted that when used in combination with the popular blood thinner, warfarin, Orbactiv could speed up the risk of bleeding.

It is expected that U.S. sales of Orbactiv could reach $150 million by 2021. Still, the FDA believes that Orbactiv’s approval does not signal the end of drug developments as more work is needed in this area, experts say.